The changing landscape in drug resistant-tuberculosis: an analysis of recent advances

Monedero, Ignacio; Caminero, José A.; Bhavaraju, Rajita; Sánchez-Montalvà, Adrián

doi:10.1586/17476348.2016.1164042

Cited by 5 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently there has been much progress in the field of MDR-TB ( 3 ), such as the introduction of rapid molecular drug susceptibility tests (DST) and the availability of new anti-TB drugs (bedaquiline and delamanid) and effective repurposed drugs (linezolid and clofazimine). In addition, a shorter MDR-TB treatment regimen has been proven effective in several cohorts ( 4 - 6 ), which has shown a high reproducibility.…”

Section: Introductionmentioning

confidence: 99%

Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design

et al. 2017

View full text Add to dashboard Cite

Detailed information on additional drug resistance patterns of multidrug-resistant tuberculosis (MDR-TB) is essential to build an effective treatment regimen; however, such data are scarce in Korea. We retrospectively analyzed the results of phenotypic drug susceptibility testing (DST) of culture confirmed-TB patients from January 2010 to December 2014 in 7 university hospitals in Korea. MDR-TB was identified among 6.8% (n = 378) of 5,599 isolates. A total of 57.1% (n = 216) of the MDR-TB patients had never been treated for TB. Strains from MDR-TB patients showed additional resistance to pyrazinamide (PZA) (35.7%), any second-line injectable drug (19.3%), and any fluoroquinolone (26.2%). Extensively drug resistant TB comprised 12.4% (n = 47) of the MDR-TB patients. Of 378 MDR-TB patients, 50.3% (n = 190) were eligible for the shorter MDR-TB regimen, and 50.0% (n = 189) were fully susceptible to the 5 drugs comprising the standard conventional regimen (PZA, kanamycin, ofloxoacin, prothionamide, and cycloserine). In conclusion, the proportion of new patients and the levels of additional drug resistance were high in MDR-TB patients. Considering the high levels of drug resistance, the shorter MDR-TB treatment regimen may not be feasible; instead, an individually tailored regimen based on the results of molecular and phenotypic DST may be more appropriate in MDR-TB patients in Korea.

show abstract

Section: Introductionmentioning

confidence: 99%

Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design

et al. 2017

View full text Add to dashboard Cite

show abstract

“…FDG PET/CT imaging allows for a better characterization of the burden of disease, suggesting a more extensive involvement than the one defined by other imaging techniques, especially for non-pulmonary TB [25,27]. Shorter drug regimens for TB treatment are urgently needed for both MDR TB and non-MDR tuberculosis, as they will reduce the appearance of resistance due to poor adherence and improve the number of successful outcomes in the programmatic management of TB [28]. To date, clinical trials in susceptible pulmonary TB aiming to demonstrate non-inferiority with shortened TB treatments have failed.…”

Section: Discussionmentioning

confidence: 99%

Usefulness of FDG PET/CT in the management of tuberculosis

et al. 2019

View full text Add to dashboard Cite

Background The aim of our study is to describe the FDG-PET/CT findings in patients with tuberculosis and to correlate them with the patient’s prognosis. Methods We retrospectively collected data from patients with tuberculosis, who had an FDG-PET/CT performed prior to treatment initiation from 2010 to 2015. Results Forty-seven out of 504 patients with active tuberculosis diagnosis (9.33%) underwent an FDG-PET/CT. The reasons for performing the FDG-PET/CT were: characterization of a pulmonary nodule (24; 51.1%), study of fever of unknown origin (12; 25.5%), study of lymph node enlargement (5; 10.6%) and others (6; 12.8%). Median age was 64 (IQR 50–74) years and 31 (66%) patients were male. Twenty-six (55.3%) patients had an immunosuppressant condition. According to the FDG-PET/CT, 48.6% of the patients had more than 1 organ affected and 46.8% had lymph node involvement. Median SUVmax of the main lesion was 5 (IQR 0.28–11.85). We found an association between the FDG accumulation and the size of the main lesion with a correlation coefficient of 0.54 (p<0.002). Patients with an unsuccessful outcome had a higher ratio SUVmax main lesion / SUVmean liver (1.92 vs 7.67, p<0.02). Conclusions In our cohort, almost half of the patients had more than 1 organ affected and 46.8% of them had lymph node involvement. FDG uptake was associated with the size of the main lesion and seems to be related to the treatment outcome. The extent of its potential to be used as an early predictor of treatment success still needs to be defined.

show abstract

Point-of-Care Devices Using Disease Biomarkers To Diagnose Neurodegenerative Disorders

Wei

Chang

et al. 2018

Trends in Biotechnology

View full text Add to dashboard Cite

The changing landscape in drug resistant-tuberculosis: an analysis of recent advances

Cited by 5 publications

References 28 publications

Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design

Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design

Usefulness of FDG PET/CT in the management of tuberculosis

Point-of-Care Devices Using Disease Biomarkers To Diagnose Neurodegenerative Disorders

Contact Info

Product

Resources

About